Pharmacological inhibition of the SUMOylation pathway: mechanisms, inhibitors and therapeutic opportunities.

Small ubiquitin-like modifier (SUMO) conjugation, or SUMOylation, is a dynamic post-translational modification that regulates protein stability, localization, transcriptional activity, DNA damage response, and cellular stress adaptation. Increasing evidence indicates that dysregulated SUMOylation contributes to tumor progression, immune disorders, and neurodegenerative diseases, highlighting the SUMO pathway as a promising therapeutic target. However, despite extensive advances in SUMO biology, a comprehensive pharmacological assessment of SUMO pathway inhibitors, including their mechanisms of action, evidence quality, target engagement, and translational challenges, remains insufficient. This review presents an inhibitor-centered analysis of pharmacological strategies targeting the SUMOylation machinery. This review describes the molecular architecture of the SUMO conjugation cycle and identifies major druggable nodes, including the SUMO-activating enzyme (SAE), the SUMO-conjugating enzyme UBC9, SUMO-specific proteases (SENPs), and SUMO-dependent protein-protein interactions. It also examines the biological rationale for SUMO pathway inhibition in major disease contexts, with an emphasis on cancer, autoimmune disorders, and neurological diseases. Furthermore, SUMO pathway modulators are systematically classified according to their molecular targets and evidence maturity, including SAE inhibitors, UBC9-directed compounds, SENP inhibitors, direct SUMO binders, and natural product-derived modulators. Their mechanisms of action, biochemical potency, structural validation, cellular target engagement, in vivo efficacy, PK/PD properties, and developmental status are critically evaluated. Overall, this review provides a comprehensive pharmacological framework for understanding SUMO pathway inhibition and highlights key considerations for the development of next-generation SUMO-directed therapeutics.